Back to today’s briefing

Story perspectives

Revolutionary HIV Drug Yeztugo Promises Two Doses Yearly

7/15/2025

38 4

Summary

Story summary

Gilead Sciences has unveiled Yeztugo (lenacapavir), an injectable HIV prevention drug that revolutionizes care with just two doses a year. The WHO champions this breakthrough, calling for swift access to this vital tool. With strong community partnerships, this initiative strives to promote health equity and tackle the HIV epidemic head-on.

1 of 1

Story summary

Gilead Sciences has unveiled Yeztugo (lenacapavir), an injectable HIV prevention drug that revolutionizes care with just two doses a year. The WHO champions this breakthrough, calling for swift access to this vital tool. With strong community partnerships, this initiative strives to promote health equity and tackle the HIV epidemic head-on.